Literature DB >> 9103401

Physical status and expression of HPV genes in cervical cancers.

J S Park1, E S Hwang, S N Park, H K Ahn, S J Um, C J Kim, S J Kim, S E Namkoong.   

Abstract

It is known that E2 protein of oncogenic human papillomavirus (HPV) inhibits the expression of E6 and E7 genes from their major promoters in vitro and suppresses the proliferation of cervical cancer cells. This suggests that the loss of functional E2 gene may provide selective advantages in the development of cervical cancer. Investigation of the relationship between the disruption of HPV-16/18 E2 genes by DNA integration and clinical outcome of cervical cancer may not only help to understand the mechanism of HPV-related cervical carcinogenesis, but may also provide novel management of cervical cancer. It was noted that integrated HPV-16/18 DNA was predominant in most patients with cervical cancers, marking 51 of a total of 68 cases (75%); episomal HPV DNAs were found in 5 cases (7.4%), and finally mixed forms of HPV DNAs with episome and integration were found in 12 cases (17.6%). Whole portions of E2 DNA of HPV-16 could be amplified by PCR in 19 (36.5%) of 52 cases of cervical intraepithelial neoplasia. It was shown that there was not statistically significant association with the different stages, but integrated HPV DNAs were detectable only in the patients with far-advanced stage of cervical cancers, which also means no episomal forms were detected. Episomal forms of HPV DNA were detectable in 14 (25.9%) of 54 squamous cell carcinomas (4 pure episomal forms and 10 mixed forms), whereas only 1 (8.3%) of 12 adenocarcinomas and adenosquamous cell carcinomas contained episomal viral DNA. When HPV DNA forms were compared with initial tumor size, lymphovascular space involvement, and frequency of nodal metastasis, statistically significant relationships were not found. The association of DNA integration with invasive cervical cancers was seen regardless of HPV type; however, there were differences between the integration profiles of HPV-16 and HPV-18 DNA. Of the 51 HPV-16-containing cancers, 36 (70.6%) revealed purely integrated HPV DNA, and another 10 cases (19.6%) displayed both integrated and episomal HPV DNAs. However, 5 (9.8%) cases showed only episomal copies of the HPV-16 genome. In contrast, all 17 HPV-18-containing cancers (5 cases positive for HPV-18 and 12 cases positive for both HPV-16 and -18) revealed only the integrated form of HPV-18 DNA. The expression of E6 and E7 transcripts of HPV-16/18 is uniformly correlated with the physical status of HPV DNAs. HPV E2 mRNAs were constantly expressed in the presence of the intact virus in cases with episome and mixed forms of HPV DNA. In general, amplified signals from HPV E2 RT-PCR are more intensive than those from DNA-PCR in the same patients. It is suggested that RT-PCR is a valuable method to evaluate dynamic expression of the specific gene and seems to be more sensitive than the DNA-PCR method in detecting intact E2 gene because of the gene copy numbers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103401     DOI: 10.1006/gyno.1996.4596

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  28 in total

1.  Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma.

Authors:  E C Pirog; B Kleter; S Olgac; P Bobkiewicz; J Lindeman; W G Quint; R M Richart; C Isacson
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line.

Authors:  Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky
Journal:  J Gen Virol       Date:  2018-04-06       Impact factor: 3.891

3.  Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines.

Authors:  E C Goodwin; L K Naeger; D E Breiding; E J Androphy; D DiMaio
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Small tumor virus genomes are integrated near nuclear matrix attachment regions in transformed cells.

Authors:  K A Shera; C A Shera; J K McDougall
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR.

Authors:  Shoji Nagao; Mitsuo Yoshinouchi; Yasunari Miyagi; Atsushi Hongo; Junichi Kodama; Sachio Itoh; Takafumi Kudo
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique.

Authors:  Panu Peitsaro; Bo Johansson; Stina Syrjänen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 7.  The role of human papillomavirus in squamous carcinoma of the head and neck.

Authors:  Guojun Li; Erich M Sturgis
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

8.  Study of viral integration of HPV-16 in young patients with LSIL.

Authors:  G Gallo; M Bibbo; L Bagella; A Zamparelli; F Sanseverino; M R Giovagnoli; A Vecchione; A Giordano
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

9.  Increase of integration events and infection loads of human papillomavirus type 52 with lesion severity from low-grade cervical lesion to invasive cancer.

Authors:  Jo L K Cheung; T H Cheung; Julian W T Tang; Paul K S Chan
Journal:  J Clin Microbiol       Date:  2008-02-13       Impact factor: 5.948

10.  The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma.

Authors:  Wei Li; Wei Wang; Mani Si; Linfei Han; Qinglei Gao; Aiyue Luo; Yan Li; Yunping Lu; Shixuan Wang; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.